Close

Anti-Peptide ESL (ESLKISQAVHAAHAEINEAGRAAAAAK+GLYC(K27)) TCR, Jurkat Cell Line (TCRJ-YC0897)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The anti-Peptide ESL (ESLKISQAVHAAHAEINEAGRAAAAAK+GLYC(K27)) TCR Jurkat cell line is a stable cell line made from the anti-Peptide ESL TCR lentivirus. The recombinant Jurkat T cell was designed to predict the MOA of Peptide ESL-TCR, measure the Peptide ESL-TCR specificity and screen target cells expressing Peptide ESL. And the product can be used to treat cytomegalovirus infection.

Specific Inquiry

  • Size:
  • Marker:
  • Positive rate:
  Add to Cart

Specifications

  • Cell Background
  • The Jurkat cell line was established from the peripheral blood of human T lymphocyte cells. Jurkat cells are used to study acute T cell leukemia, T cell signaling, and the expression of various chemokine receptors. Jurkat cells can produce interleukin 2, and are used in research involving the susceptibility of cancers to drugs and radiation.
  • Cell Type
  • T lymphocyte
  • Formulation
  • Containing ≥ 1 X 10*6 / vial frozen cells
  • Cell Purity
  • >95%
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • The cell line has been screened using the luciferase based mycoplasma detection kit to confirm the absence of mycoplasma species.
  • Applications
  • • Screen for activators or inhibitors of CMV signaling in a cellular context
    • Characterize the biological activity of CMV and its interactions with ligands
    • Predict the MOA of the TCR design
    • Screen and validate CMV-expressing target cells
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C). Once reconstituted, the cells may be used for up to five days if properly stored at 2°C - 8°C in the buffer provided.
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Warnings
  • Avoid multiple freeze/thaw cycles
  • Research Use Only
  • Our recombinant Jurkat cell are for research use only, not for diagnostic or therapeutic use.
  • Quality Control
  • Cultures are screened for the presence of bacteries, yeast, fungi and mycoplasma (DNA amplification). Growth media are also certified based on U.S. Public Health Service Guidelines.
  • Tumorgenicity
  • Positive (In vitro/vivo transformation assay)
  • Oncogenicity
  • Positive (In vitro soft agarose assay and life-time studies )
  • Sterility Testing
  • Creative Biolabs provides sterility testing in accordance with USP and EP regulations. All of our sterility testing is performed in an isolator or clean room environments. The cell line has been screened using the membrane filtration testing methods to confirm the absence of aerobic, anaerobic and fungi microorganisms.
  • Identity Testing
  • Identity testing is required for newly established cell lines. Isoenzyme analysis is used to confirm the identity of the species of a cell line. Alternative methods for identity testing include DNA fingerprinting, STR analysis and karyology.
  • Virological Safety Testing
  • A broad range of viruses is susceptible to affecting human cell lines. We can provide in vivo/vitro virus saftey assays by utilizing various animal systems. These viruses include: adventitious viruses, bovine viruses, human and simian viruses, porcine viruses, retrovirus and rodent viruses.
  • Genetic Stability Testing
  • We perform cell genetic stability studies under ICH guidelines. We can provide guidance on the appropriate testing program upon your requirements.

TCR Design

  • Target
  • Peptide ESL
  • Introduction
  • Vaccination with synthetic long peptides (SLPs), covering viral or tumor epitopes, has shown promising results in experimental models and recently also in clinical therapeutic vaccination trials. This peptide-based vaccine platform allows covering multiple (overlapping) MHC classes I and II epitopes and therefore does not require the necessity for HLA-typing for each patient to be treated. Moreover, in contrast to short peptides, SLPs are not able to bind directly to MHC class I and their presentation to CD8+ T cells therefore requires uptake and processing by antigen-presenting cells (APCs) such as dendritic cells (DCs) before they are presented. This is advantageous, as properly activated dendritic cells (DCs) are vital for the strength of the ensuing T-cell responses. Other immune cells for example generally lack the capacity to provide adequate T cell costimulation and thus may cause tolerance. The efficacy of a particular peptide vaccine is however influenced by many parameters and its success ranges from inducing clinical efficacy to detrimental effects such as hyperreactivity and hyporesponsiveness. Mechanistic studies with peptide vaccines in different experimental models revealed that by more specific targeting, improving the uptake of SLPs, and/or activation of APCs the SLP-based vaccines generally advance leading to better clinical success.
  • HLA
  • H2 class II
  • Common Name
  • Peptide ESL
  • TCR Clone
  • OT-II
  • TCR-Host Animal
  • Mouse
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • Epitope
  • ESLKISQAVHAAHAEINEAGRAAAAAK + GLYC(K27)
  • Format
  • Non-Modified TCR

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-Peptide ESL (ESLKISQAVHAAHAEINEAGRAAAAAK+GLYC(K27)) T Cell Receptor (OT-II), Jurkat Cell Line (TCRJ-YC0897). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.